NIAID Now

7 Results

HIV Treatment Research and Key Takeaways: Dr. Dieffenbach’s Final Update from CROI 2024 (VIDEO)

On March 6 as the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) was winding down, HIV.gov spoke with Carl Dieffenbach, Ph.D., director of NIAID's Division of AIDS, about highlights of long-acting HIV treatment research discussed at the conference. He spoke with Brian Minalga, M.S.W., deputy director of the NIH-supported Office of HIV/AIDS Network Coordination. Watch their conversation.

Centering Women and Girls’ Health in HIV Research

Women account for approximately 23 percent of people with HIV in the United States. In recent years, women aged 25 to 34 comprised the highest number of new diagnoses. Furthermore, Black women, transgender women, and women aged 13 through 24 are more likely to experience health disparities associated with lack of access to HIV testing, treatment, and prevention resources. This weekend marked National Women and Girls HIV/AIDS Awareness Day. NIAID supports research programs that focus on HIV and other health outcomes in women to inform and enable more targeted and effective HIV prevention, care, and treatment.

Doxy-PEP, HIV Vaccines and Community-Engaged Research: Discussions with Carl Dieffenbach and LaRon Nelson at CROI 2024 (VIDEO)

During the first full day of presentations at the 2024 Conference on Retroviruses and Opportunistic Infections, HIV.gov spoke with Carl Dieffenbach, Ph.D., director of NIAID’s Division of AIDS, and LaRon Nelson, Ph.D., R.N., F.N.P., F.N.A.P., F.N.Y.A.M., F.A.A., professor and associate dean at the Yale School of Nursing. They discussed Doxy-PEP for STI prevention, HIV vaccines, community engagement in research, and more. Watch their discussions.

NIAID’s Dr. Jeanne Marrazzo Previews CROI 2024 (VIDEO)

HIV.gov opened their coverage of the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) today with a conversation with NIAID Director Jeanne Marrazzo, M.D., M.P.H. She spoke with Miguel Gomez, director of HIV.gov about what she’s looking forward to hearing about at the conference, how the studies presented at research conferences ultimately get translated into clinical practice or HIV prevention or treatment services, and the important roles of early-career investigators. Watch their conversation with Dr. Marrazzo.

Working Together to End HIV in Black Communities

Health inequities and disparities disproportionately affect Black people and other historically marginalized groups at above average rates. NIAID highlights ongoing efforts to reduce the burden of HIV among Black Americans while increasing the representation of Black communities and researchers in HIV science.

The STOMP trial evaluates an antiviral for mpox

NIAID launched the STOMP trial to determine whether the antiviral drug tecovirimat can safely and effectively treat mpox. Watch Dr. Cyrus Javan of NIAID's Division of AIDS explain the importance of the STOMP trial.

NIAID-Supported Research is Advancing the Response to Surging Syphilis Rates

Syphilis, a common sexually transmitted infection (STI) caused by the bacteria Treponema pallidum, can result in adult neurological and organ damage, as well as congenital abnormalities, stillbirths, and neonatal deaths. More research is urgently needed to diversify the diagnostic, preventive, and therapeutic options available to alter the course of the public health threat of syphilis. NIAID supports research to address these areas including studies featured at the recent STI & HIV World Congress in Chicago.

Contact

Contact the NIAID Media Team.
301-402-1663

niaidnews@niaid.nih.gov